HIV drug switch may protect hearts, early study suggests
NCT ID NCT04820933
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 31 times
Summary
This early-phase study tested whether switching HIV medications to doravirine (with emtricitabine and tenofovir alafenamide) could reduce heart disease risk in 26 adults with well-controlled HIV and high cholesterol. Researchers measured how the change affected HDL function and other early signs of artery damage. The goal was to see if doravirine is a more heart-friendly option for long-term HIV management.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR RISK FACTOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Texas Southwestern
Dallas, Texas, 75219, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75219, United States
Conditions
Explore the condition pages connected to this study.